Key facts
- US lawmakers are intensifying scrutiny of biotechnology connections with China.
- This increased oversight is creating uncertainty for Chinese drugmakers regarding overseas licensing and development deals.
- The situation poses a threat to a significant growth channel for Chinese pharmaceutical companies seeking international partnerships.
US lawmakers' efforts to scrutinize biotechnology relationships with China are creating apprehension among Chinese pharmaceutical companies regarding their international licensing and development agreements. This growing oversight threatens a vital and expanding avenue through which domestic drugmakers have been forging connections with global pharmaceutical giants. The increased scrutiny could significantly impact the future of cross-border collaborations in the innovative drug sector.